A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma.
AffiliationManchester Cancer Research Centre, Faculty of Biology, Medicine& Health, Division of Cancer Sciences, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT
MetadataShow full item record
AbstractThe BRAF-kinase and the MAPK-pathway are targets of current melanoma therapies. However, MAPK-pathway inhibition results in dynamic changes of down-stream targets that can counteract inhibitor-action not only during treatment, but also in acquired resistant tumours. One such dynamic change involves the expression of the transcription factor MITF, a crucial regulator of cell survival and proliferation in untreated as well as drug-addicted acquired resistant melanoma. Tight control over MITF expression levels is required for optimal melanoma growth, and while it is well established that the MAPK-pathway regulates MITF expression, the actual mechanism is insufficiently understood. We reveal here, how BRAF through action on the transcription factors BRN2 and PAX3 executes control over the regulation of MITF expression in a manner that allows for considerable plasticity. This plasticity provides robustness to the BRAF mediated MITF regulation and explains the dynamics in MITF expression that are observed in patients in response to MAPK-inhibitor therapy. This article is protected by copyright. All rights reserved.
CitationA PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma. 2018, Pigment Cell Melanoma Res
JournalPigment Cell & Melanoma Research
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
- Authors: Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS
- Issue date: 2014 Dec 15
- A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
- Authors: Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA
- Issue date: 2014 Jul
- Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
- Authors: Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R
- Issue date: 2008 Jul 16
- Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.
- Authors: Berlin I, Denat L, Steunou AL, Puig I, Champeval D, Colombo S, Roberts K, Bonvin E, Bourgeois Y, Davidson I, Delmas V, Nieto L, Goding CR, Larue L
- Issue date: 2012 Apr
- Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
- Authors: Kundu A, Quirit JG, Khouri MG, Firestone GL
- Issue date: 2017 Jan